Pi3k-alpha inhibitors and methods of making and using the same

A process for preparing a crystalline form of a compound of Formula (I), comprising:

• a) preparing a solution of a compound of Formula (I):
• b) adjusting the temperature so that solid crystalline form of a compound of Formula (I) precipitates out of the solution;
• and c) isolating the solid crystalline form.

A process for preparing a crystalline form of a compound of Formula (II), comprising:

• a) preparing a solution of a compound of Formula (II):
• b) adjusting the temperature so that solid crystalline form of a compound of Formula (II) precipitates out of the solution;
• and c) isolating the solid crystalline form.

A process for preparing a crystalline form of a compound of Formula (III), comprising:

• a) preparing a solution of a compound of Formula (III):
• b) adjusting the temperature so that solid crystalline form of a compound of Formula (III) precipitates out of the solution;
• and c) isolating the solid crystalline form.

A compound of Formula (IV-1)

• or a pharmaceutically acceptable salt thereof.

A compound of Formula (IV-2)

• or a pharmaceutically acceptable salt thereof.

A process for preparing a compound of Formula IV-1 and a compound of Formula IV-2, comprising deuteration of compound III-1 followed by a purification step to separate the enantiomers, thereby forming compounds IV-1 and IV-2:

A process for preparing a compound of Formula I-1 and a compound of Formula I-2, comprising subjecting compound III-1 to a SMB separation, for example, as described in Example 1-A, thereby forming compounds I-1 and II-1:

A process for preparing a compound of Formula III-1, comprising a racemization of compound II-1: